Bone Therapeutics signs research partnership with Implant
Therapeutics to access induced Pluripotent Stem Cells (iPSC)
REGULATED INFORMATION
Bone Therapeutics will gain access to iPS cell
lines, including hypoimmunogenic cell lines, differentiation
protocols and expertise
iPSC technology allows for the development of
next-generation cell therapy products as a key addition to Bone
Therapeutic’s existing cell therapy platform
Gosselies, Belgium and Beltsville, MA,
US, 28 September 2021, 7.00 am
CEST – BONE THERAPEUTICS (Euronext
Brussels and Paris: BOTHE), the cell therapy company addressing
unmet medical needs in orthopedics and other diseases, and
IMPLANT THERAPEUTICS, the developer of
hypoimmunogenic and safe harbor engineered IPSC derived cells,
today announced the signing of a research evaluation agreement. The
agreement will enable Bone Therapeutics to access, evaluate and
materially transfer Implant Therapeutics’ Induced Pluripotent Stem
Cell (iPSC) lines, media, differentiation protocols and
expertise.
Bone Therapeutics has developed a cutting-edge
bone marrow-derived off-the-shelf, allogeneic MSC cell therapy
platform. Its allogeneic cell therapy product, ALLOB, currently in
clinical trials for different orthopedic indications, has resulted
from this platform. Bone Therapeutics is now utilizing its
expertise to broader clinical indications of high unmet medical
need as previously communicated. To achieve this strategic aim, it
is now expanding its sources of MSCs from those derived from bone
marrow and implementing genetic modification of MSCs to achieve
higher therapeutic efficacy.
Bone Therapeutics has partnered with Implant
Therapeutics to gain access to iPSC derived, genetically engineered
MSCs. These specific single source MSCs are highly standardized,
are expandable and scalable. They are also more flexible with
regards to modification methodologies, including gene editing and
transduction, than existing autologous and allogeneic approaches.
This specific agreement is set to last twelve months, and be
focused on achieving early-stage research and product design and
testing. Bone Therapeutics will initially perform technology
evaluation, product design and optimization of these iPSC derived
MSCs. Bone Therapeutics and Implant Therapeutics will discuss an
agreement covering commercial R&D and commercialization stages
of development as required.
Bone Therapeutics will, in parallel, continue to
research and evaluate a number of genes that are of interest as
well as genetic modification technologies and methodologies. This
separate activity will be undertaken to enhance the functionality
and efficacy of MSCs for specific indications.
“Unmodified MSC-based products have already
generated positive efficacy signals across the industry. Bone
Therapeutics believes that greater efficacy can be further achieved
by professionalizing and tailoring the functionality of the cells
for each indication, as Bone Therapeutics has already achieved for
ALLOB,” said Tony Ting, CSO, Bone
Therapeutics. “To address further, life-threatening
indications with high levels of mortality and a significant unmet
medical need, it will be essential to genetically engineer MSCs.
This will give these cells the ammunition they need to tackle
difficult diseases. The agreement with Implant Therapeutics allows
Bone Therapeutics to access specific and advantageous iPSC derived
MSCs and utilize its iPSC expertise, including that of Mahendra
Rao, a renowned world-class expert in the field. His expertise,
knowhow and support are highly valuable components and a key
motivation behind this collaboration.”
“Implant Therapeutics has acquired technologies
and considerable specialist knowledge to build our portfolio of
iPSC derived MSCs. This expertise will be of specific use to Bone
Therapeutics as it utilises our iPSC derived MSCs to expand its
indications,” said Dr. Mahendra Rao, founder, Implant
Therapeutics. “We will continue to work with Bone
Therapeutics as it develops and integrates these iPSC derived MSCs
to address significant unmet medical needs.”
About Implant TherapeuticsImplant
provides hypoimmunogenic and safe harbor engineered IPSC derived
cells in order to deliver the ultimate therapeutic MSC products. To
learn more, visit https://www.implant-rx.com/
About Bone Therapeutics
Bone Therapeutics is a leading biotech company
focused on the development of innovative products to address high
unmet needs in orthopedics and other diseases. The Company has a
diversified portfolio of cell therapies at different stages ranging
from pre-clinical programs in immunomodulation to mid stage
clinical development for orthopedic conditions, targeting markets
with large unmet medical needs and limited innovation.
Bone Therapeutics’ core technology is based on
its cutting-edge allogeneic cell and gene therapy platform with
differentiated bone marrow sourced Mesenchymal Stromal Cells (MSCs)
which can be stored at the point of use in the hospital. Currently
in pre-clinical development, BT-20, the most recent product
candidate from this technology, targets inflammatory conditions,
while the leading investigational medicinal product, ALLOB,
represents a unique, proprietary approach to bone regeneration,
which turns undifferentiated stromal cells from healthy donors into
bone-forming cells. These cells are produced via the Bone
Therapeutics’ scalable manufacturing process. Following the CTA
approval by regulatory authorities in Europe, the Company has
initiated patient recruitment for the Phase IIb clinical trial with
ALLOB in patients with difficult tibial fractures, using its
optimized production process. ALLOB continues to be evaluated for
other orthopedic indications including spinal fusion, osteotomy,
maxillofacial and dental.
Bone Therapeutics’ cell therapy products are
manufactured to the highest GMP (Good Manufacturing Practices)
standards and are protected by a broad IP (Intellectual Property)
portfolio covering ten patent families as well as knowhow. The
Company is based in the BioPark in Gosselies, Belgium. Further
information is available at www.bonetherapeutics.com.
For further Implant Therapeutics
information, please contact:
Implant TherapeuticsLisa
Schummer, Manager OperationsTel: +1
(888)-613-6862lisa@pancella.com
For further information, please
contact:
Bone Therapeutics SAMiguel
Forte, MD, PhD, Chief Executive OfficerLieve Creten, Chief
Financial Officer ad interimTel: +32 (0)71 12 10
00investorrelations@bonetherapeutics.com
For Belgian Media and Investor
Enquiries:BepublicCatherine HaquenneTel: +32
(0)497 75 63 56catherine@bepublic.be
International Media Enquiries:Image Box
CommunicationsNeil Hunter / Michelle BoxallTel: +44 (0)20
8943 4685neil.hunter@ibcomms.agency / michelle@ibcomms.agency
For French Media and Investor
Enquiries:NewCap Investor Relations & Financial
CommunicationsPierre Laurent, Louis-Victor Delouvrier and
Arthur RouilléTel: +33 (0)1 44 71 94 94bone@newcap.eu
Certain statements, beliefs and opinions in this
press release are forward-looking, which reflect the Company or, as
appropriate, the Company directors’ current expectations and
projections about future events. By their nature, forward-looking
statements involve a number of risks, uncertainties and assumptions
that could cause actual results or events to differ materially from
those expressed or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, competition and technology, can cause actual
events, performance or results to differ significantly from any
anticipated development. Forward looking statements contained in
this press release regarding past trends or activities should not
be taken as a representation that such trends or activities will
continue in the future. As a result, the Company expressly
disclaims any obligation or undertaking to release any update or
revisions to any forward-looking statements in this press release
as a result of any change in expectations or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither the Company nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the forecasted
developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.